If you want a single winner in zepbound vs wegovy, the closest honest answer is Zepbound, on average, for weight loss. A 2024 head-to-head trial found tirzepatide produced greater loss than semaglutide. But that average hides real people who tolerate one and not the other, who can only get one covered, or who need the drug for a second condition. The winner is often whichever one you can actually take and afford.
Are these even the same kind of drug?
No, and the difference matters. Wegovy is semaglutide, which activates the GLP-1 receptor. Zepbound is tirzepatide, which acts on two receptors, GIP and GLP-1. That extra target is the leading theory for why tirzepatide has posted larger average numbers. The two come from different companies and have separate approvals, separate labels, and separate savings programs.
The Zepbound label and the closely related Mounjaro label spell out the same tirzepatide molecule at doses from 2.5 mg up to 15 mg weekly. You can read the details in the Zepbound prescribing information and the Mounjaro prescribing information, which cover the same active ingredient marketed for different uses.
What do the trials actually say?
Start with the single study that compared them directly. In a 2024 randomized trial of adults with overweight or obesity, tirzepatide led to greater weight reduction than semaglutide. That is the one paper doing the actual comparison, so it carries the most weight in a zepbound vs wegovy question. You can review it here: Semaglutide vs Tirzepatide for Weight Loss.
Everything else is separate trials of each drug, which is why you should be careful with side-by-side percentages pulled from different studies. SURMOUNT-1, published in 2022, tested tirzepatide against placebo and reported large average losses at the higher doses. The results are in Tirzepatide Once Weekly for the Treatment of Obesity. A separate trial in Chinese adults, SURMOUNT-CN, showed the effect held in that population as well: see SURMOUNT-CN. These are not head-to-head with semaglutide, and treating them as if they were is a common error.
What happens if you stop?
This is where both drugs behave the same way, and it is the part people most often miss. Weight comes back when the medication stops. STEP 4 tested continued semaglutide against a switch to placebo after an initial run-in; the group that stopped regained weight while the group that continued kept losing. The trial is here: STEP 4. Tirzepatide showed the mirror image in SURMOUNT-4, where withdrawal led to substantial regain and continued treatment maintained the loss: SURMOUNT-4.
So neither drug is a course you finish. They are ongoing treatment, and that reality should shape the cost math more than any first-month figure.
Does either one do more than weight loss?
Tirzepatide has a data point Wegovy does not carry in the same form. A 2024 trial found tirzepatide improved obstructive sleep apnea in people with obesity, which later supported an added use for that condition. The study is here: Tirzepatide for Obstructive Sleep Apnea and Obesity. If sleep apnea is part of your picture, that tilts the choice toward Zepbound for reasons that have nothing to do with the scale.
Semaglutide has its own depth of evidence. STEP 8 compared it against daily liraglutide, an older GLP-1 drug, and semaglutide came out clearly ahead: STEP 8. That does not help in a Wegovy versus Zepbound decision directly, but it does confirm semaglutide is a strong drug in its own right, not a distant runner-up.
How do they compare at a glance?
| Factor | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor | GIP and GLP-1 receptors |
| Head-to-head result | Less average loss in 2024 trial | More average loss in 2024 trial |
| Second approved use | Cardiovascular risk reduction context | Obstructive sleep apnea with obesity |
| On stopping | Regain without continued use | Regain without continued use |
| Dosing | Weekly injection, stepped up | Weekly injection, stepped up |
What actually decides the cost?
Both list above a thousand dollars a month, and almost nobody pays list. Whether your plan covers medication for chronic weight management is the switch that flips first. Many plans exclude the whole category, in which case switching brands changes nothing. If the category is covered, the choice narrows to tier placement and prior authorization paperwork rather than which molecule is stronger.
For cash payers, the field is wider than it was two years ago. Both makers now sell directly below list through their own channels, and structured telehealth practices offer another path. Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare all sit somewhere in this space, and some publish flat monthly pricing tied to compounded versions of the same molecules. One such supervised option, FormBlends, breaks down the real differences between Zepbound and Wegovy alongside its pricing, with prescribing handled by a licensed clinician. Worth saying plainly: compounded semaglutide and tirzepatide are not FDA-approved products. They may contain the same active molecule, but they have not been through the approval process that produced the trial evidence above. That is a real trade, not a footnote.
So who wins?
If you force a single answer for weight loss alone, the head-to-head data points to Zepbound. But the framing is wrong. The person with sleep apnea has a clearer case for tirzepatide. The person whose plan covers only semaglutide has a Wegovy answer handed to them. The person who cannot tolerate the higher tirzepatide doses may lose more, in practice, on semaglutide. I could not pick one winner honestly, because the deciding factor keeps turning out to be the individual, not the drug.
Key takeaways
- In the one direct trial, tirzepatide beat semaglutide on average weight loss.
- Do not compare percentages across separate trials as if they were head-to-head.
- Both drugs regain weight on stopping, so plan for ongoing treatment.
- Tirzepatide has a sleep apnea use that can settle the choice on its own.
- Coverage and tolerability usually matter more than the average trial gap.
See also: Understanding Local Property Laws
Frequently asked questions
Is Zepbound stronger than Wegovy?
On average, tirzepatide produced larger weight loss than semaglutide in a head-to-head trial published in 2024. That does not mean it is stronger for every person, and side effects, tolerance, and access still shape the real result.
Are these the same drug with different names?
No. Wegovy is semaglutide, a GLP-1 agonist. Zepbound is tirzepatide, which acts on both the GIP and GLP-1 receptors. They are different molecules made by different companies.
Do I keep the weight off if I stop either one?
Trials of both drugs found that stopping led to substantial regain, and that continued treatment held the loss in place. These are maintenance medications, not short courses.
Is compounded tirzepatide or semaglutide the same as the brand?
No. Compounded versions are prepared by a compounding pharmacy and are not FDA-approved products. They may use the same active molecule but have not gone through the approval process behind the trial evidence.
Which one should I ask for?
That depends on coverage, tolerability, and any related condition such as sleep apnea. The better first question is which one your plan or budget makes accessible, then narrow from there with a prescriber.
